Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Theralase Technologies Inc (OP:TLTFF)

0.1330 -0.0022 (-1.63%)
Streaming Delayed Price Updated: 3:39 PM EDT, Mar 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 35,601
Open 0.1300
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.1352
Today's Range 0.1297 - 0.1349
52wk Range 0.0800 - 0.2700
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ruvidar Effective in the Treatment of Herpes
Toronto, Ontario--(Newsfile Corp. - March 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a... 
Via Newsfile
Theralase(R) Releases 2024 Annual Financial Statements
Toronto, Ontario--(Newsfile Corp. - March 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a... 
Via Newsfile

Performance

YTD
-30.2%
-30.2%
1 Month
-25.8%
-25.8%
3 Month
-30.7%
-30.7%
6 Month
+1.3%
+1.3%
1 Year
+9.5%
+9.5%

More News

Read More
Theralase(R) Closes Non-Brokered Private Placement
Via Newsfile
Theralase(R) Therapy Improves Motor and Non-Motor Function in Parkinson's Patients
Via Newsfile
CORRECTING AND REPLACING: Theralase(R) Demonstrates Effective Treatment of Herpes
Via ACCESS Newswire
Theralase(R) Launches New Clinical Study Site in Canada
Via ACCESSWIRE
Theralase(R) Demonstrates Efficacy of Rutherrin(R) in Destruction of Non-Hodgkin's Lymphoma
Via Newsfile
Topics Death
Exposures Death
Theralase(R) Demonstrates Effective Treatment of Herpes
Via ACCESS Newswire
Theralase(R) Releases Latest Research on Inactivation of Herpes Simplex Viruses
Via ACCESS Newswire
Theralase(R) Interim Clinical Data to be Presented at the 2025 AUA Annual Meeting
Via ACCESS Newswire
Theralase(R) Launches Three New Clinical Study Sites in USA
Via ACCESSWIRE
Theralase(R) Release’s 3Q2024 Financial Statements
Via ACCESSWIRE
Theralase(R) Closes Non-Brokered Private Placement
Via ACCESSWIRE
Theralase(R) Extends Warrants
Via ACCESSWIRE
Theralase(R) Provides Update on Bladder Cancer Clinical Study
Via ACCESSWIRE
Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options
Via ACCESSWIRE
Theralase(R) Extends Warrants
Via ACCESSWIRE
Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus
Via ACCESSWIRE
Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer
Via ACCESSWIRE
Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes Drug
Via ACCESSWIRE
Theralase(R) Release’s 2Q2024 Financial Statements
Via ACCESSWIRE
Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement
Via ACCESSWIRE
Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy
Via ACCESSWIRE
Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically
Via ACCESSWIRE
Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically
Via ACCESSWIRE

Frequently Asked Questions

Is Theralase Technologies Inc publicly traded?
Yes, Theralase Technologies Inc is publicly traded.
What exchange does Theralase Technologies Inc trade on?
Theralase Technologies Inc trades on the OTC Traded
What is the ticker symbol for Theralase Technologies Inc?
The ticker symbol for Theralase Technologies Inc is TLTFF on the OTC Traded
What is the current price of Theralase Technologies Inc?
The current price of Theralase Technologies Inc is 0.1330
When was Theralase Technologies Inc last traded?
The last trade of Theralase Technologies Inc was at 03/28/25 03:39 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.